A phase I, single- and repeated-dose, randomized, open-label, multicenter study to evaluate the pharmacokinetics, pharmacodynamics and safety of lansoprazole in infants with clinically-evident gastroesophageal reflux disease.
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Lansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors Takeda
- 05 Nov 2005 New trial record.